Catalyst Wire Dossier Catalyst Wire Dossier

NVA237 (glycopyrronium bromide)

glycopyrronium bromide · Novartis
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for NVA237 (glycopyrronium bromide), covering 2011-01-21 to 2011-01-21. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium [Phase 2]

See pricing